Clinical Trial Update: DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of DCVax-L vaccination combined with CD3/CD28-costimulated autologous T-cells for recurrent ovarian cancer or primary peritoneal cancer has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CD3/CD28 costimulated autologous T-cells (CD3/CD28 costimulated autologous T-cells)
• DCVax-L

Snippet

Sponsor: University of Pennsylvania | Conditions: Ovarian Cancer, Primary Peritoneal Cancer | Phase 1, Phase 2 | Status: WITHDRAWN